Abstract
Several studies have linked 5-HT1A C1019G and BDNF G196A (Val66Met) gene polymorphisms to major depressive disorder (MDD) and the actions of antidepressants. We attempt to show that the interaction between 5-HT1A and BDNF polymorphism predicts the risk of treatment-resistant depression. The sample consists of 119 patients with treatment-resistant MDD and 392 controls. 5-HT1A C1019G and BDNF G196A (Val66Met) polymorphisms were studied. The combination of 5-HT1A GG and BDNF GA + AA genotypes is associated with an increased risk of depression.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antidepressive Agents / pharmacology
-
Brain / drug effects
-
Brain / metabolism
-
Brain / physiopathology
-
Brain Chemistry / drug effects*
-
Brain Chemistry / genetics
-
Brain-Derived Neurotrophic Factor / genetics*
-
DNA Mutational Analysis
-
Depressive Disorder / genetics*
-
Depressive Disorder / metabolism
-
Depressive Disorder / therapy
-
Drug Resistance / genetics*
-
Electroconvulsive Therapy / statistics & numerical data
-
Female
-
Gene Frequency / genetics
-
Genetic Markers / genetics
-
Genetic Predisposition to Disease / genetics*
-
Genetic Testing
-
Genotype
-
Humans
-
Male
-
Middle Aged
-
Polymorphism, Genetic / genetics
-
Receptor, Serotonin, 5-HT1A / genetics*
-
Risk Factors
-
Serotonin / metabolism
-
Treatment Failure
Substances
-
Antidepressive Agents
-
Brain-Derived Neurotrophic Factor
-
Genetic Markers
-
Receptor, Serotonin, 5-HT1A
-
Serotonin